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Abstract. Identification of neurodegeneration-monitoring biomarkers would be of great clinical value for Alzheimer’s disease
(AD) diagnosis. Using N- or C-terminal antibodies, we studied the pro-survival synaptic effector, Kidins220, in the brain and
cerebrospinal fluid (CSF) of controls and AD patients. Only the N-terminal antibody showed a positive correlation between
Kidins220 and phosphorylated tau in AD brains. Using this antibody, Kidins220 was detected in CSF from AD patients
where it positively correlated with CSF phosphorylated tau and tau. This study highlights the potential of Kidins220 as a CSF
biomarker in AD.
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INTRODUCTION22
Alzheimer’s disease (AD), the most prevalent age-23
related dementia, is characterized by progressive24
neurodegeneration and severe synaptic and neuronal25
loss. Neuropathological hallmarks of AD are extra-26
cellular senile plaques containing amyloid- (A)27
and intracellular neurofibrillary tangles enriched in
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28
hyperphosphorylated tau [1, 2]. Currently, reduced 29
A1–42 and increased phosphorylated tau (p-tau) 30
and tau levels in the cerebrospinal fluid (CSF) are 31
used as diagnostic markers for AD [3, 4]. How- 32
ever, additional biomarkers for the early stages of 33
AD pathogenesis could help improve AD diagnosis 34
and monitor neurodegeneration. To this end, synap- 35
tic proteins in the CSF represent good candidates for 36
further improving the prognostic accuracy of the AD 37
biomarker panels [4]. 38
Kinase D interacting substrate of 220 kDa 39
(Kidins220) [5], also known as ankyrin repeat-rich 40
membrane spanning “ARMS” [6], is an integral 41
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membrane protein present at the synapse where42
it is critical for neurotrophin and NMDARs sig-43
naling and neuronal survival [7, 8]. Dysfunctional44
neurotrophic support, synaptopathy, and excitotoxi-45
city (pathological overstimulation of the glutamate46
N-methyl-D-aspartate receptors; NMDARs) are47
involved in AD neurodegeneration [9], making48
Kidins220 a promising candidate.49
We have previously demonstrated an increase in50
Kidins220 in brains from AD patients concomitantly51
with Braak stage progression [10]. We also observed52
that, at late Braak stages, Kidins220 accumulates53
within hyperphosphorylated tau aggregates of dys-54
trophic neurites. Indeed, Kidins220 associates and55
shares common features with tau [10]. However,56
despite this initial observation, a thorough study of the57
correlation between Kidins220 and tau accumulation58
in the AD brain has yet to be reported.59
Here we have evaluated Kidins220 levels in AD60
and control brain samples, examining the poten-61
tial correlation with tau. Due to the potential for62
Kidins220 as a biomarker for underlying neurode-63
generation, we have also analyzed Kidins220 levels64
in CSF samples from our cohort of patients.65
MATERIALS AND METHODS66
Antibodies67
C-terminal and N-terminal Kidins220 rabbit68
polyclonal antibodies (Kidins220-Ct and Kidins220-69
Nt) and Kidins220 mouse monoclonal antibody70
(Kidins220-M) have been previously described [5,71
11, 12]. Neuronal specific enolase (NSE) rabbit72
polyclonal antibody was from Millipore Corporation73
(Billerica, MA, USA). A (6E10) and -actin mouse74
monoclonal antibodies were from Covance (Salt Lake75
City, UT, USA) and Sigma-Aldrich (St. Louis, MO,76
USA) respectively. PHF-1-p-tau antibody was a gift77
from Dr. Davies (Albert Einstein College, NY, USA).78
Tau rabbit polyclonal antibody was purchased in79
DakoCytomation (Glostrup, Denmark).80
Human brain samples81
Brain tissue was collected by the Neurological82
Tissue Bank (Hospital Clı´nic, IDIBAPS, Barcelona,83
Spain) and the Neuropathology Institute Brain Bank84
(Hospital Universitari de Bellvitge, Hospitalet de85
Llobregat, Spain). Tissue collection and use was86
approved by the local Ethics Committee of the Tissue87
Bank and IIB-SantPau.88
Immunoblot analysis 89
Protein brain homogenates and CSF sam- 90
ples (30l) were analyzed by SDS-PAGE and 91
immunoblot as previously described [10]. 92
Clinical cohort 93
Subjects from the Memory Unit (Hospital Santa 94
Creu I Sant Pau) underwent formal cognitive 95
evaluation [13] by neurologists with expertise in neu- 96
rodegenerative diseases. Cognitively healthy control 97
subjects showed results within the normal range and 98
were negative for the core AD biomarkers based 99
on our in-house criteria (CSF A1-42 >550 ng/ml, 100
CSF t-tau <350 ng/ml or CSF p-tau <61 ng/ml) [14]. 101
Patients with amnesic mild cognitive impairment 102
(aMCI) were diagnosed according to NIA-AA crite- 103
ria [15]. Patients with aMCI who were also positive 104
for AD biomarkers (CSF A1–42 <550 ng/ml, CSF 105
t-tau >350 ng/ml or CSF p-tau >61 ng/ml) were 106
classified as Prodromal AD due to the increased prob- 107
ability of conversion to AD [15]. Patients who met 108
the criteria of the National Institute of Neurologi- 109
cal and Communicative Disorders and Stroke and the 110
Alzheimer’s Disease and Related Disorders Associ- 111
ation [16] and were positive for AD biomarkers were 112
classified as typical AD. All participants gave their 113
written consent, and the study was approved by the 114
local ethics committee following the ethical standards 115
recommended by the Helsinki Declaration. 116
CSF collection and assessment 117
Collection of CSF was achieved by lumbar 118
puncture according to international consensus rec- 119
ommendations [17]. Quantification of AD CSF 120
biomarkers by ELISA was performed as previously 121
described [14]. 122
Quantiﬁcation and statistical analysis 123
Full-length (FL) Kidins220 was quantified by den- 124
sitometric analysis (NIH Image) after immunoblot- 125
ting with Kidins220-Ct. Quantification values using 126
Kidins220-Nt resulted from the sum of signals from 127
FL and N-terminal fragments in brain or only FL 128
in CSF. Kidins220 levels were normalized to NSE 129
in brain samples and to Ponceau staining in CSF 130
samples, and expressed relative to the mean of con- 131
trols. Signal for p-tau was normalized to tau and 132
to NSE in brain samples. Student’s t-test was used 133
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to compare Kidins220 levels between controls and134
patients. Correlations between Kidins220, p-tau, tau135
and A1–42 were determined by Spearman’s Corre-136
lation test. Statistical analyses were performed using137
GraphPad Prism (San Diego, CA, USA).138
RESULTS139
Short postmortem interval and detection140
of Kidins220 N-terminal region are critical141
factors to study Kidins220 in human brain142
Initial studies on Kidins220 in AD were carried143
out on postmortem brain samples using an antibody144
raised against the last 17 amino acids of Kidins220145
C-terminus (Kidins220-Ct) [10]. We have previously146
shown that Kidins220 very C-terminal end is lost147
after cleavage by the protease calpain in models148
of excitotoxicity and cerebral ischemia, and that149
cleaved-forms of the protein could only be detected150
by an antibody recognizing the N-terminal region151
(Kidins220-Nt) [7, 18]. Therefore, Kidins220-Ct sig-152
nal could be severely diminished in situations where153
this protease is highly active, while the N-terminal154
signal may be preserved (see Fig. 1A for details of155
antibodies and calpain-cleaved Kidins220 N-terminal156
fragments).157
Because calpain is activated in postmortem tissue158
[19], we first evaluated the influence of postmortem159
interval (PMI) on the ability of C-terminal and N-160
terminal antibodies to identify Kidins220 in human161
brain tissue. In order to strictly study the effect of162
increasing PMI, control and AD brain samples of163
short PMI (6 and 5 h, respectively) were left at room164
temperature for additional periods of time before ana-165
lyzing Kidins220 by immunoblot (Fig. 1B). Both166
antibodies detected a band corresponding to FL167
Kidins220 but, as time increased, FL signal disap-168
peared and N-terminal fragments emerged, being still169
visible after 24 h only with Kidins220-Nt (Fig. 1B).170
Kidins220-Ct did not detect any proteolytic band (not171
shown).172
With this in mind, we examined Kidins220 lev-173
els using these two antibodies in brain necropsies174
over a range of PMI from AD patients and control175
individuals (see Supplementary Table 1 for clin-176
ical and demographic information). Quantification177
analysis of immunoblots showed that FL-Kidins220178
detected by Kidins220-Ct negatively correlated with179
PMI both in control and AD samples (Fig. 1C,180
left; r2(Cont, black line) = 0.197, n = 15, p < 0.05;181
r2(AD, grey line) = 0.311, n = 20, p < 0.05). How-182
ever, Kidins220-Nt signal, considered as the sum 183
of FL and N-terminal fragments, showed no signifi- 184
cant correlation with PMI (Fig. 1C, right; r2(Cont, 185
black line) = 0.009, n = 15, p > 0.05; r2(AD, grey 186
line) = 0.145, n = 20, p > 0.05). No differences in 187
Kidins220 levels according to age or Braak stage were 188
found using Kidins220-Nt (not shown). 189
Kidins220 positively correlates with p-tau 190
in human AD brain necropsies using a novel 191
N-terminal antibody 192
Next, we compared Kidins220 levels between 193
AD and control brain necropsies with a PMI of 194
less than 8 h to avoid potential loss of signal 195
due to long PMI. Immunoblot and quantification 196
analysis using both antibodies showed increased 197
levels of Kidins220 in AD versus control samples 198
(Fig. 1D, E), being differences more evident with 199
Kidins220-Nt (p < 0.01) compared to Kidins220- 200
Ct (p < 0.05). Furthermore, Kidins220-Nt revealed 201
a positive correlation between Kidins220 and p-tau 202
in AD samples (r2 = 0.236, n = 17, p < 0.05) (Fig. 1F). 203
Finally, immunofluorescence of human AD brain 204
showed partial co-localization of Kidins220 with 205
p-tau (Fig. 1G). 206
Kidins220 is present in CSF samples from AD 207
patients and correlates with tau 208
In order to evaluate Kidins220 as a CSF biomarker, 209
CSF samples were obtained from 12 controls, 5 210
patients with aMCI, 4 prodromal AD, and 9 AD 211
patients (see Supplementary Table 1 for demographic 212
details). Immunoblot analysis with Kidins220-Nt 213
showed Kidins220 presence, clearly more evident 214
in some CSF samples from AD patients, while 215
Kidins220-Ct rendered no specific bands (Fig. 2A). 216
To confirm specificity of Kidins220 signal in CSF 217
samples, we also tested a monoclonal antibody gener- 218
ated against 340 amino acids of Kidins220 C-terminal 219
region (Kidins220-M) [12]. This antibody detected 220
FL-Kidins220 in those AD samples with higher 221
Kidins220-Nt signal (Fig. 2A). Although Kidins220- 222
Nt labeled different bands in CSF, it was difficult to 223
undoubtedly identify the specific bands correspond- 224
ing to the N-terminal fragments. Therefore, we only 225
quantified Kidins220-FL-Nt band, and found it was 226
significantly increased in CSF samples from AD 227
patients (Fig. 2B). In addition, in these patients there 228
was a positive correlation between CSF Kidins220- 229
Nt and p-tau (Fig. 2C; r2(Cont, black line) = 0.003, 230
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Fig. 1. The use of an antibody recognizing Kidins220 N-terminal region is critical to study Kidins220 levels in postmortem human brain
samples and their correlation with phospho-tau in AD. A) Scheme of Kidins220 domains and regions recognized by the antibodies used.
Estimated molecular weight of calpain-derived N-terminal fragments is also shown. Kidins220-Ct recognizes last 17 amino acids. Kidins220-
Nt was generated against the first 402 amino acids. B) Immunoblot analysis of control and AD brain samples (6 and 5 h PMI, respectively,
considered time 0) left at room temperature for different times using Kidins220-Ct and Kidins220-Nt. Kidins220 full-length (FL) and N-
terminal fragments are indicated. C) Correlation analysis of Kidins220 levels versus PMI obtained after immunoblot analysis of control and
AD brain samples using Kidins220-Ct (left panel) and Kidins220-Nt (right panel) antibodies (Cont, black, n = 15; AD, grey line and color
scale for Braak stages, n = 20). Kidins220 values are given in arbitrary units expressed relative to the loading control NSE. D) Immunoblot
analysis of a representative number of protein extracts from frontal cortex necropsies obtained from control subjects and AD patients.
FL-Kidins220, Nt-fragments and proteins analyzed are indicated. E) Scatter dot plots analysis of the immunoblot bands after quantifying
Kidins220 levels in control and AD brain samples using Kidins220-Ct (left panel) or Kidins220-Nt (right panel) antibodies. Kidins220 values
are expressed in arbitrary units (a.u.) relative to the values of NSE and relative to the mean of the control group. Each symbol represents an
individual (Cont, black, n = 13; AD, grey line and color scale, n = 17). Data show means ± s.e.m. Unpaired t-test was performed (∗p < 0.05,
∗∗p < 0.01). F) Correlation analysis of Kidins220 versus p-tau levels from control and AD brain using Kidins220-Nt. Kidins220 and p-tau
values are given in arbitrary units (a.u.) expressed relative to tau and NSE. Each symbol represents an individual (Cont, black, n = 12; AD,
grey line and color scale n = 13). Correlation analyses were based on the Pearson’s analysis (∗p < 0.05). G) Immunofluorescence of Kidins220
(red) and p-tau (green) in human AD brain. Nuclei were stained with DAPI. Scale bar: 20m.
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Fig. 2. Kidins220 is present in CSF from AD patients containing high levels of p-tau and tau. A) Immunoblot analysis of CSF samples from
control subjects and patients diagnosed for aMCI, typical AD (AD) and atypical AD (AD*) (see Supplementary Table 1 for details) using
Kidins220-Ct, Kidins220-Nt, and Kidins220-M antibodies. FL-Kidins220 is indicated. Extracts from cultured rat cortical neurons (Neu) are
included as positive control for Kidins220 signal. B) Scatter dot plots analysis of Kidins220-FL-Nt signal in CSF samples. Kidins220 values
are expressed in arbitrary units (a.u.) relative to the values of total protein after Ponceau staining and relative to the mean of the control
group. Each symbol represents an individual (Cont, n = 10; aMCI, n = 5; pro AD, n = 4; AD+AD*, n = 9). Data show means ± s.e.m. Unpaired
t-test was performed (∗p < 0.001). C, D) Correlation analysis of Kidins220 versus p-tau and tau levels from control and AD patients using
Kidins220-Nt. Kidins220 values are given in arbitrary units (a.u.) and p-tau and tau levels in pg/ml. Each symbol represents an individual
(Cont, black, n = 10; AD+AD*, grey line and color n = 9). Correlation analyses were based on the Pearson’s analysis (∗p < 0.05, ∗∗p < 0.01).
n = 9; r2(AD, grey line) = 0.744, n = 9, p > 0.01), and231
tau (Fig. 2D; r2(Cont, black line) = 0.001, n = 9;232
r2(AD, grey line) = 0.494, n = 9, p > 0.05) but no sig-233
nificant correlation with A1–42 was found.234
DISCUSSION235
To evaluate Kidins220 as a potential biomarker236
for neurodegeneration, we have performed a quan-237
titative study of Kidins220 in brain necropsies and238
CSF samples. Kidins220 was detected in human239
brain by immunoblot using two polyclonal antibodies240
that recognize either the carboxy- or amino-termini241
of Kidins220. We found a negative correlation242
between Kidins220 levels and PMI in human brain243
necropsies, which was specific to the use of the C- 244
terminal antibody. Moreover, only the N-terminal 245
Kidins220 signal correlated with p-tau levels in AD 246
brains. Importantly, Kidins220-Nt antibody detected 247
Kidins220 in CSF samples from AD patients where 248
it correlated positively with p-tau and tau content. 249
Our results suggest that Kidins220 could constitute 250
a novel marker of AD neurodegeneration. 251
In some CSF samples, Kidins220 band was also 252
visible using a monoclonal antibody raised against 253
a big portion of Kidins220 C-terminal region but 254
not with Kidins220-Ct that recognizes only last 17 255
amino acids. These findings indicate that CSF may 256
contain mainly N-terminal fragments of Kidins220 257
lacking the very C-terminal end after cleavage at the 258
major identified calpain site (see scheme in Fig. 1A), 259
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as has been reported in the ischemic brain [18].260
The presence of transmembrane proteins in CSF261
is possible since cell-derived small vesicles known262
as exosomes have been detected in this biological263
fluid [20]. Indeed, transmembrane amyloid-related264
protein, as well as cytosolic proteins associated to265
exosomes such as tau, are found in CSF [21, 22]. In266
addition, excitotoxic calpain-derived Kidins220 N-267
terminal fragments could be formed intracellularly268
during neurodegeneration and released to the extra-269
cellular space, associated to exosomes or free, as270
a consequence of neuronal death.271
Our data demonstrate that Kidins220-Nt is a bet-272
ter tool for obtaining accurate and reproducible273
results in explorative studies of human postmortem274
and CSF samples than Kidins220-Ct. The diagnos-275
tic and/or prognostic value of CSF Kidins220 needs276
to be explored in larger clinical longitudinal stud-277
ies. More sensitive and specific methods to detect278
small amounts of this protein in CSF (such as ELISA)279
would be greatly beneficial for future studies.280
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